$0.28
(0.49%)
Create an alert
Stocks and Shares ISAGSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Company Information
About this company
Key people
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Phil C. Thomson
President - Global Affairs
Deborah Waterhouse
Chief Executive Officer - ViiV Healthcare and President - GSK Global Health
Hal V. Barron
Non-Executive Director
Elizabeth McKee Anderson
Independent Non-Executive Director
Luke Miels
Chief Executive Officer, Executive Director
Charles A. Bancroft
Senior Independent Non-Executive Director
Anne Beal
Independent Non-Executive Director
Julie Brown
Chief Financial Officer, Executive Director
Lynn Baxter
President, Europe
Mike Crichton
President, International
Maya Martinez-Davis
President, US
Nina Mojas
President - Global Product Strategy
David S. Redfern
President - Corporate Development
Regis Simard
President - Global Supply Chain
Click to see more
Key facts
- Shares in issue4.32bn
- EPICGSK
- ISINUS37733W2044
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$117.53bn
- Employees66,841
- ExchangeNew York Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.